Heparan sulfate vs diosmin: Effects on microcirculation in chronic venous insufficiency of the lower extremities

Advances in Therapy

Volumn 13, Issue 3, 1996, Pages 178-190

  Cospite, Michele ^a   Milio, Glauco ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

chronic venous insufficiency; diosmin; heparan sulfate; postthrombotic syndrome

Indexed keywords

DIOSMIN; HEPARAN SULFATE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD RHEOLOGY; CHRONIC VEIN INSUFFICIENCY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYSIS; HUMAN; LEG BLOOD FLOW; MALE; MICROCIRCULATION; ORAL DRUG ADMINISTRATION; POSTTHROMBOSIS SYNDROME; RANDOMIZED CONTROLLED TRIAL; VARICOSIS;

EID: 0029900088     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Fransson LA. Heparansulphate proteoglicans: structure and properties. In: Lane DA, Lindhal U, eds. Heparin: Chemical and Biological Properties, Clinical Applications. London, England: Edward Arnold; 1989:124-127.
2. Segre G. Aspetti farmacologici dei glicosaminoglicani. Minerva Med. 1986;77:1859-1864.
3. Del Guercio R, Del Guercio M, Leonardo G. Microcircolazione ed eparansolfato. Minerva Angiol. 1993;18(suppl 1):265-266.
4. Allegra C. Endotelio come organo. Patologia vascolare ed eparansolfato. Milano, Italy: Pragma; 1991.
5. Marcum JA, McKenney JB, Galli SJ, Jackman RW, Rosemberg RD. Anticoagulantly active heparin-like molecules from mast cell deficient mice. Am J Physiol. 1986;250:H879.
6. Chanquia CJ, Corominas M, Sierra A, Fontcuberta J. Profibrinolitic activity of heparan sulphate on human endothelial cells. Eur Bull Drug Res. 1992;1(2):78-84.
7. Casu R, Johnson EA, Mantovani M, et al. Correlation between structure, fat clearing and anticoagulant properties of heparin and heparan sulphates. Arzneim Forsch-Drug Res. 1983;33(1):135-142.
8. Gallagher JT, Walker A. Molecular distinction between heparansulphate and heparin. Analysis of sulphation patterns indicates that heparansulphate and heparin are separate families of N-sulfate polysaccharides. Biochem J. 1985:230:665-674.
9. Larsson A, Fransson LA, Lewis WE. Demonstration of a direct anti-factor Xa activity in certain heparin related glycosaminoglycans. Thromb Res. 1982;26(6):401-409.
10. Thomas DP, Merton RE, Barrowcliffe TW, Mulloy B, Johnson EA. Anti factor Xa activity of heparansulphate. Thromb Res. 1979;14(2-3):501-506.
11. Ofosu, FA, Modi GJ, Smith LM, Cerskus AL, Hirsh MA, Blajchman MA. Heparansulphate and dermatansulphate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood. 1984;64(3):742-747.
12. Cenni A, Puliti R, Viggiani P, Spignoli G. Effects of heparan sulphate on coagulation and fibrinolysis. Pharmacol Res. 1989;21:651-652.
13. Bekemejer H, Hirschelmann R, Giessler AJ. Carragenin-induced thrombosis in rats and mice: a model for testing antithrombotic substances? Agents Actions. 1985;16:446-451.
14. Bollu J, Kumar S. Effects of heparin, heparan sulphate and dermatan sulphate on fibrinolysis by tissue plasminogen activator. FASEB J. 1988;2(4):A227.
15. Viggiani P, Puliti R, De Regis M, Cenni A, Spignoli G. Investigation on the antithrombotic activity of heparan sulphate. J Drug Devel. 1989;2:49-53.
16. Browse NL, Burnard KG, Lea Thomas L, eds. Diseases of the Veins. London, England: Edward Arnold; 1988.
17. Pratesi F. Microcircolo e microangiologia. Torino, Italy: Minerva Medica; 1990.
18. Allegra C, Carlizza A, Inglese A, Pannitteri G, Pollari G, Tonelli V. Considerazioni clinico epidemiologiche su una popolazione di flebopatici. Atti Giornate Flebologiche Algheresi. 1989:167.
19. Mari A, Bonafacio M, Carlizza A, et al. Clinical epidemiological considerations in a phlebopathic population. Proceedings of the 15th World Congress of the International Union of Angiology, September 17-22,1985; Rome, Italy, 1:599.
20. Cochran WG. Statistical Methods. 6th ed. Ames, Iowa: The Iowa State University Press; 1976:419-476.